Polaris Group (北極星藥業集團) yesterday said that phase 3 clinical trials for its mesothelioma treatment ADI-PEG 20 has been successful, adding that it plans to apply next year for marketing approval with the US Food and Drug Administration (FDA).
The trials showed that two main test gauges reached statistical significance, Polaris said, referring to overall survival (OS) — the time a patient survives from the beginning of treatment — and progression-free survival (PFS) time — the time a patient’s cancer does not worsen from the beginning of treatment.
The median OS time for the 125 participants treated with ADI-PEG 20 was 9.3 months, 21.4 percent higher than 7.66 months for the 124 participants in the control group, Polaris said.
The median PFS time was 6.11 months, compared with 5.59 months for the control group, it said.
The trials showed that 98.4 percent and 8.8 percent of all participants in the test group reported adverse events and serious adverse effects respectively, lower than 99.2 percent and 9.7 percent in the control group, it added.
“The small difference between the ratios of people with adverse effects in the two groups signifies the safety of ADI-PEG 20,” it said.
The trials were conducted in 38 hospitals in five countries: Taiwan, the US, the UK, Australia and Italy, it said.
As Polaris in February received the FDA’s fast-track designation, its application for marketing approval would be expedited, Polaris chairman Howard Chen (陳鴻文) told a news conference, adding that the company plans to submit the application at the beginning of next year.
Even though the number of people with mesothelioma is not high, totaling 38,000, the company is confident about the drug’s sales prospects, Chen said.
As Polaris developed ADI-PEG 20 with a metabolism-based strategy that depletes arginine, which causes stress and cytotoxicity in tumors, it could continue to try combining ADI-PEG 20 with other chemotherapy drugs for treating other kinds of cancer, the company said.
Polaris said that cumulative revenue in the first eight months of this year plunged 40 percent year-on-year to NT$5.55 million (US$176,527).
Apple Inc might make one out of four iPhones in India by 2025, JPMorgan & Chase Co analysts said yesterday, as the tech giant moves some production away from China, amid mounting geopolitical tensions and strict COVID-19 lockdowns in the country. JPMorgan expects Apple to move about 5 percent of iPhone 14 production from late this year to India, which is the second-biggest smartphone market in the world after China. It is also estimating that about 25 percent of all Apple products, including Mac, iPad, Apple Watch and AirPods, would be manufactured outside China by 2025 from 5 percent currently. The US company
HEADING SOUTH: The US company chose Kaohsiung as its site as more customers, partners and start-ups have expanded their operations to the southern city Qualcomm Inc yesterday inaugurated a new innovation center in Kaohsiung as it steps up efforts to foster local start-ups and a 5G technology ecosystem in the city, following in the footsteps of its local partners. The US chip company’s move fits the Kaohsiung City Government’s plan to build a semiconductor supply chain within the next five years, highlighted by Taiwan Semiconductor Manufacturing Co’s (TSMC, 台積電) first chip plant in the city. TSMC plans to start building the factory by the end of this year, and to start production of 28-nanometer and 7-nanometer chips there in 2024. Qualcomm said it had been
SLUMPING DEMAND: Inventory has climbed by up to 12 weeks as suppliers are under mounting pressure to offload excessive reserves, a TrendForce report said The price of DRAM chips is expected to fall at a steeper rate of 13 to 18 percent next quarter, as high inflation continues to weigh on demand for consumer electronics, causing chip inventories to soar, market researcher TrendForce Corp (集邦科技) said yesterday. The downtrend in DRAM prices could extend from a quarterly decline of 10 to 15 percent in the third quarter, the Taipei-based researcher said. “Demand for consumer electronics continued to stagnate during the third quarter, which used to be a high demand season,” TrendForce said in a statement. “During the quarter, memorychip consumption and shipments both showed quarterly
GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines. GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology. Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research